Lexeo Therapeutics, Inc. Common Stock / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €325.41M +155.5% €57.49M -182.1% 17.7% +0.73 pp N/A N/A
    (estimated) €127.39M +420.0% -€70.04M -24.4% -55.0% +3.2 pp N/A N/A
    (estimated) €24.50M +∞% -€92.68M -4.0% -378.3% -3.8 pp -€61.24M -9.0% -250.0% -2.5 pp
    (estimated) €0.00 +NaN% -€96.56M +1.1% N/A -€67.28M -27.1% N/A
    (estimated) €0.00 +NaN% -€95.47M +12.6% N/A -€92.30M +32.6% N/A
    €0.00 +NaN% -€84.82M +48.1% N/A -€69.59M +36.0% N/A
    €0.00 -100.0% -€57.27M +12.0% N/A -€51.18M +10.6% N/A
    €564.13K -60.5% -€51.13M +17.1% -9,063.8% -60 pp -€46.29M +22.0% -8,204.7% -55 pp
    €1.43M +219.6% -€43.67M +882.4% -3,055.0% -21 pp -€37.95M +1,304.0% -2,655.0% -21 pp
    €447.23K -€4.44M -993.8% -€2.70M -604.3%

    Notifications